Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy Laboratories Limited, commented: “Ranbaxy and Gilead have a strong collaboration in the area of HIV/AIDS. We are pleased to extend this association with Gilead that will enable us to offer quality affordable medicines for the treatment of HIV/AIDS in developing countries.”Arun Kumar, Managing Director and Group Vice-Chairman, Strides Arcolab Ltd., commented: “We are pleased to associate with Gilead on this initiative that will provide access to high quality essential antiretrovirals in developing markets. This partnership will re-enforce our commitment to provide affordable drugs in the field of HIV/AIDS, tuberculosis and malaria to low- and middle-income countries.”
Gilead Sciences Announces New Collaboration With Indian Partners To Reduce Manufacturing Cost And Improve Availability Of Emtricitabine-Based Antiretroviral Therapy In Developing Countries
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.